cas 1698293-93-4|| where to buy 4-methyl-2-propan-2-ylpyridin-3-amine

Produktname:4-methyl-2-propan-2-ylpyridin-3-amine

IUPAC Name:4-methyl-2-(propan-2-yl)pyridin-3-amine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM325577-10g	in stock	Ţƞ
CM325577-25g	in stock	ŉĽǵ
CM325577-100g	in stock	ĽŢź

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1698293-93-4 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1698293-93-4; Molekulare Formel:C9H14N2; Schmelzpunkt:-; SMILES-Code:NC1=C(C)C=CN=C1C(C)C; Dichte:

: Katalognummer:CM325577; Molekulargewicht:150.23; Siedepunkt:; Mdl-Nr.:; Lagerung:Store at 2°C~8°C

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Glecirasib; On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.